GlassScriptPhysician profile
Sandy M Gibson
NPI 1548220288
$4,767.97
in general payments reported to CMS, 2019-2025
30 companies · $1,258 in 2025
The $1,258 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,294 · 2020: $529 · 2021: $286 · 2022: $326 · 2023: $416 · 2024: $659 · 2025: $1,258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,957 · Education: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,957.19 |
| Education | $375.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $609.31 | 2019-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $606.12 | 2019-2024 | Jynarque |
| Amgen INC. | $503.19 | 2019-2025 | Krystexxa |
| Vifor Pharma, INC. | $419.17 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $325.03 | 2019-2025 | Rayaldee |
| Akebia Therapeutics INC | $289.36 | 2019-2024 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $277.11 | 2022-2025 | Filspari |
| Ardelyx, INC. | $206.81 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $204.79 | 2023-2025 | |
| Fresenius USA Marketing, INC. | $185.37 | 2019-2025 | Velphoro, Velphoro |
| Ani Pharmaceuticals, INC. | $160.56 | 2023-2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $148.13 | 2024-2025 | Zepbound, Jardiance |
| Mallinckrodt Hospital Products INC. | $140.09 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.91 | 2024-2025 | Jardiance |
| Ascendis Pharma Endocrinology INC | $63.37 | 2025 | Yorvipath |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $57.74 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Vanda Pharmaceuticals INC. | $55.99 | 2020 | |
| Aurinia Pharma U.S., INC. | $54.40 | 2023 | Lupkynis |
| Nxstage Medical, INC. | $47.26 | 2022 | |
| Cycle Pharmaceuticals INC | $43.64 | 2025 | Venxxiva |
| Calliditas Therapeutics US INC. | $40.80 | 2023 | Tarpeyo |
| Baxter Healthcare | $36.79 | 2019 | |
| Horizon Therapeutics Plc | $36.36 | 2023 | Krystexxa |
| Cormedix INC. | $31.23 | 2025 | Defencath |
| E.R. Squibb & Sons, L.L.C. | $30.19 | 2025 | Zeposia |
| Shield Therapeutics INC | $26.83 | 2025 | |
| Outset Medical INC | $24.09 | 2023 | |
| Kyowa Kirin, INC. | $20.40 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.99 | 2025 | |
| Janssen Pharmaceuticals, INC | $14.94 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandy Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.